Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 02/21 04:16:43 pm
64.61 EUR   +0.09%
02/20SANOFI : anofi diverting attention from real issues' -- Gordon
AQ
02/19SANOFI : Disclosure of trading in own shares
GL
02/19Stronger European Earnings Augur More M&A, Higher Dividends
DJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Pharmaceuticals - NEC
08:39aMERCK : to Invest Additional EUR40 Million in Asia
DJ
08:15aMerck to buy virus-based cancer drug firm Viralytics for $394 million
RE
06:27aMERCK AND : to Buy Australia's Viralytics for $394 Million
DJ
02:48aNOVARTIS : Builds Up R&D -- WSJ
DJ
02:48aABBVIE : FTC Clout Tested in Suit Versus Drugmaker -- WSJ
DJ
02/20MERCK : and Partners Start EUR20 Million Israel Biotech Fund
DJ
02/19BASF to face millions in extra costs in UK each year from Brexit - Handelsbla..
RE
02/19UK shares retreat as Reckitt disappoint
RE
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19NOVARTIS : Correction to Novartis CEO story
DJ
02/19Stronger European Earnings Augur More M&A, Higher Dividends
DJ
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
RE
02/19ASTRAZENECA : Cell Lung Cancer Treatment Imfinzi Gets FDA Approval
DJ
02/18NOVARTIS : CEO Steers Drug Maker Back to R&D
DJ
02/16S&P 500 caps off strongest week in five years
RE
02/16ASTRAZENECA : U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
RE
02/16NOVARTIS : readies to auction U.S. generic pills business - sources
RE
02/16Backstory - Warren Buffett's Valentine's Day surprise for investors
RE
02/16BACKSTORY : Warren Buffett's Valentine's Day surprise for investors
RE
02/16WARREN BUFFETT : Warren Buffett's Valentine's Day surprise for investors
RE
02/16Pot Pharm - Booming Canada weed sector plots next-wave medicines
RE
02/16POT PHARM : Booming Canada weed sector plots next-wave medicines
RE
02/15ROCHE : to buy Flatiron Health for $1.9 billion to expand cancer care portfolio
RE
02/15ROCHE : to buy Flatiron Health for $1.9 billion to expand cancer care portfolio
RE
02/15ROCHE : to Acquire Healthcare-Software Company Flatiron for $1.9 Billion
DJ
02/15AbbVie to buy back $10 billion of shares, raises dividend
RE
02/15AbbVie to buy back $10 billion of shares, raises dividend
RE
02/15ABBVIE : Increases Dividend and Announces New Stock Repurchase Program
DJ
02/15Cyclicals, South Africa-exposed stocks help steady FTSE 100
RE
02/15European shares build on recovery, Airbus shines
RE
02/15MERCK : and Pfizer's Avelumab Fails to Meet Endpoint in Lung Cancer Trial -- Upd..
DJ
02/15MERCK : and Pfizer's Avelumab Fails to Meet Endpoint in Lung Cancer Trial
DJ
02/15Growth formula eludes under-fire Nestle, L'Oreal stake unchanged
RE
02/15Indivior bets on $1 billion anti-addiction shot as legal bill weighs
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15SHIRE PLC SHIRE PLC : Director/Pdmr Shareholding
DJ
02/15BAYER : Syngenta aims to sell bonds within weeks, M&A important - CFO
RE
02/15COLOPLAST A/S : ConvaTec beats low full-year expectations, shares rise
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/15ASTRAZENECA : Says Selumetinib Granted FDA Orphan Drug Status
DJ
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14SHIRE : 4Q Product Sales and Generic Competition in Focus -- Earnings Review
DJ
02/14BAYER : Gets FDA Warning Over Manufacturing Practices at German Site
DJ
02/14SHIRE : 4Q Profit Rises on U.S. Tax Reform
DJ
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -9-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -8-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -7-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -6-
DJ
02/14SHIRE PLC SHIRE PLC : Final Results -5-
DJ
Financials (€)
Sales 2018 35 367 M
EBIT 2018 8 919 M
Net income 2018 5 324 M
Debt 2018 11 557 M
Yield 2018 4,76%
P/E ratio 2018 14,94
P/E ratio 2019 13,58
EV / Sales 2018 2,62x
EV / Sales 2019 2,44x
Capitalization 81 220 M
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
SANOFI-11.62%100 124
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%226 667
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 826
MERCK AND COMPANY-0.50%153 359
AMGEN3.23%132 827
BRISTOL-MYERS SQUIBB COMPANY6.64%112 867
ABBOTT LABORATORIES2.12%104 732
BAYER-6.36%100 852
NOVO NORDISK A/S-8.76%100 588
GLAXOSMITHKLINE-1.67%91 862
ELI LILLY AND COMPANY-8.80%86 953
ASTRAZENECA-7.96%83 737
CELGENE CORPORATION-9.55%70 592
ALLERGAN PLC1.86%54 557
TAKEDA PHARMACEUTICAL CO LTD-9.08%43 383
SHIRE-18.46%39 143
JIANGSU HENGRUI MEDICINE CO LTD4.28%32 165
ASTELLAS PHARMA INC5.31%29 316
CHUGAI PHARMACEUTICAL CO LTD-2.95%29 086